A WORLD WITHOUT INFECTIOUS DISEASE



Vir Biotechnology, Inc.

Effector Function Deep Dive
October 5, 2020

Legal disclaimers

Forward-Looking Statements

Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our goals with respect to the prophylaxis or treatment of SARS-CoV-2/COVID-19, Vir-7831's potential differentiation compared to other antibodies, the potential effect of the effector function and Vir-7831's potential to treat COVID-19. Words such as "believe," "anticipate," "plan," "expect," "intend," "will," "may," "goal," "potential" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based on the beliefs of the management of Vir Biotechnology, Inc. (the "Company") as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about the Company, including, without limitation, risks inherent in developing the Company's products and technologies, future results from the Company's ongoing and planned clinical trials such as unexpected data or clinical site activation rates or clinical trial enrollment rates that are lower than expected, difficulties arising from our collaborations, challenges in accessing adequate manufacturing capacity, the Company's ability to obtain adequate financing to fund its planned clinical trials and other expenses, trends in the industry, changes in the competitive landscape, delays or disruptions due to the COVID-19 pandemic, the legal and regulatory framework for the industry, unexpected litigation or disputes and future expenditures. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The actual results may vary from the anticipated results and the variations may be material. Other factors that may cause the Company's actual results to differ from current expectations are discussed in the Company's filings with the U.S. Securities and Exchange Commission, including the section titled "Risk Factors" contained therein. These forward-looking statements should not be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such forward-looking statements have been made are correct or exhaustive or, in the case of the assumptions, fully stated in this presentation. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this presentation is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. The Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 for all forward-looking statements.

This presentation discusses product candidates that are under clinical study and which have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied. This presentation also discusses the results of a publicly-available, independent pre-clinical research report, which is still under peer review and which Vir has had no role in. No representation is made to the validity of the findings of such a report.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.

© 2020 Vir Biotechnology, Inc.

How VIR-7831 is potentially differentiated

- Potent neutralization
- **Effector function**
- High barrier to resistance
- “LS” modification
  - Half-life extension could mean one dose potentially lasts up to 6 months for prophylaxis
  - Potential for increased lung bioavailability

The neutralization potency, ability to kill infected cells, high barrier to resistance of VIR-7831 are based on non-clinical assessments

© 2020 Vir Biotechnology, Inc.

Antibodies for treatment: importance of neutralization

Monoclonal antibodies that neutralize the virus



block *uninfected cells* from becoming infected

© 2020 Vir Biotechnology, Inc.

Antibodies for treatment: neutralization is not enough

Unfortunately, already infected cells remain



and continue to mass produce SARS-CoV-2 virus

© 2020 Vir Biotechnology, Inc.

Antibodies for treatment: killing already infected cells is potentially critical



VIR-7831 can recruit macrophages and NK cells to kill already infected cells (in vitro effector function assays),

while also protecting uninfected cells

NK, natural killer.

© 2020 Vir Biotechnology, Inc.

Currently under peer review: antibody assessment of effector function in COVID animal models

- Schafer et al. *Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo*
- *Some of the authors include:*
  - Timothy P. Sheahan, University of North Carolina at Chapel Hill, Chapel Hill, NC
  - Ralph S. Baric, University of North Carolina at Chapel Hill, NC
  - Jeffrey V. Ravetch, Rockefeller University, NY
  - Michel C. Nussenzweig, Rockefeller University, NY
- VIR Biotechnology had no role in this study
- Currently available to the public at bioRxiv @ https://www.biorxiv.org/content/10.1101/2020.09.15.298067v1

© 2020 Vir Biotechnology, Inc.

In vitro neutralization and In vivo viral load reduction of 7 different COVID-19 antibodies



C002 has in vitro neutralization that is 6x more potent than C104 (29.9 vs 176.9). **C002 has less potency in vivo then C104.**

C104 is the most potent antibody in vivo, despite having the highest IC90 of any antibody tested.

https://www.biorxiv.org/content/10.1101/2020.09.15.298067v1

© 2020 Vir Biotechnology, Inc.

Impact of effector function knock out (GRLR) on In vivo viral load reduction



The knock-out of effector function (C002-GRLR) has no clear impact on C002, suggesting C002-WT has limited native effector function. This may explain its inferior performance compared to C104 in vivo.

"Knocking-out" native effector function (C104-GRLR) results in an antibody which has similar in vivo potency to C002-WT.

WT = intact effector function
GRLR = effector function knock-out mutant

https://www.biorxiv.org/content/10.1101/2020.09.15.298067v1

© 2020 Vir Biotechnology, Inc.